Cortisol abnormal – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cortisol abnormal – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion/ Wed, 29 Apr 2026 14:58:01 +0000 https://clinicaltrials.eu/trial/study-on-metyrapone-for-patients-with-mild-autonomous-cortisol-secretion/ This clinical trial is focused on studying a condition known as mild autonomous cortisol secretion, which involves the body producing too much of a hormone called cortisol. The treatment being tested in this study is a medication called Metycor, which contains the active substance metyrapone. Metyrapone works by inhibiting an enzyme in the adrenal gland, which helps reduce the production of cortisol.

The purpose of the study is to assess whether treatment with Metycor can improve certain health conditions related to excess cortisol, such as high blood pressure, issues with blood sugar levels, and overall cortisol levels. Participants in the study will take Metycor for a period of six months. During this time, their health will be monitored to see if there are improvements in these areas.

Throughout the study, participants will have their blood pressure and blood sugar levels checked, and their cortisol levels will be measured. The study will also look at other health factors, such as weight, cholesterol levels, and quality of life. The goal is to determine if Metycor can help manage the symptoms associated with mild autonomous cortisol secretion and improve the overall health of the participants.

]]>